Business Description
Sanofi SA
ISIN : FR0000120578
Share Class Description:
WBO:SANO: Ordinary SharesTotal Employee Number:
74,846Compare
Compare
Traded in other countries / regions
SAN.FranceSNY.USA0O59.UKSNW.Germany1SAN.ItalySAN1N.MexicoSNY.CanadaSANO.AustriaSNW.BulgariaSAN.Switzerland IPO Date
2017-10-04Description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | 1.63 | |||||
Interest Coverage | 15.33 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.56 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | -1.8 | |||||
3-Year EPS without NRI Growth Rate | -2.9 | |||||
3-Year FCF Growth Rate | -4.2 | |||||
3-Year Book Growth Rate | -0.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.62 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.23 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.24 | |||||
9-Day RSI | 55.56 | |||||
14-Day RSI | 53.27 | |||||
3-1 Month Momentum % | -5.66 | |||||
6-1 Month Momentum % | -9.54 | |||||
12-1 Month Momentum % | -9.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 0.73 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 272.84 | |||||
Days Sales Outstanding | 62.24 | |||||
Days Payable | 205 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.41 | |||||
Dividend Payout Ratio | 0.63 | |||||
3-Year Dividend Growth Rate | 5.6 | |||||
Forward Dividend Yield % | 5.41 | |||||
5-Year Yield-on-Cost % | 6.84 | |||||
3-Year Average Share Buyback Ratio | 1.4 | |||||
Shareholder Yield % | 10.2 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.07 | |||||
Operating Margin % | 20.54 | |||||
Net Margin % | 16.72 | |||||
EBITDA Margin % | 26.71 | |||||
FCF Margin % | 15.44 | |||||
OCF Margin % | 23.01 | |||||
ROE % | 10.71 | |||||
ROA % | 6.09 | |||||
ROIC % | 7.04 | |||||
3-Year ROIIC % | -12.01 | |||||
ROC (Joel Greenblatt) % | 49.6 | |||||
ROCE % | 6.85 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.97 | |||||
Forward PE Ratio | 9.1 | |||||
PE Ratio without NRI | 12.17 | |||||
Shiller PE Ratio | 13.18 | |||||
Price-to-Owner-Earnings | 8.81 | |||||
PS Ratio | 2 | |||||
PB Ratio | 1.29 | |||||
Price-to-Tangible-Book | 24.16 | |||||
Price-to-Free-Cash-Flow | 12.97 | |||||
Price-to-Operating-Cash-Flow | 8.7 | |||||
EV-to-EBIT | 15.59 | |||||
EV-to-Forward-EBIT | 10.2 | |||||
EV-to-EBITDA | 8.5 | |||||
EV-to-Forward-EBITDA | 8.4 | |||||
EV-to-Revenue | 2.27 | |||||
EV-to-Forward-Revenue | 2.12 | |||||
EV-to-FCF | 14.7 | |||||
Price-to-GF-Value | 0.71 | |||||
Price-to-Projected-FCF | 0.76 | |||||
Price-to-Median-PS-Value | 0.71 | |||||
Price-to-Graham-Number | 3.61 | |||||
Earnings Yield (Greenblatt) % | 6.41 | |||||
FCF Yield % | 7.9 | |||||
Forward Rate of Return (Yacktman) % | 1.96 |
Sanofi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sanofi SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 | In 109 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 07:00 | In 18 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 17 days | ||
| EUR 4.120000 Cash Dividend | 2026-05-05 | 77.73 (-2.86%) | ||
| General meeting for 2026 | 2026-04-29 | 79.00 (+1.20%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 07:00 | 80.97 (+0.81%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 80.97 (+0.81%) | ||
| Annual report for 2025 | 2026-02-18 | 78.25 (+1.32%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-01-29 08:30 | 77.93 (-0.87%) |
Show
Entries
Press Release
Articles on Sanofi SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers